/CGON
CGON Stock - CG Oncology, Inc. Common stock
Healthcare|BiotechnologyNASDAQ
$39.03+2.71%
+$1.03 (+2.71%) • Dec 19
75
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.67
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.68
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+81.3%upside
Target: $70.76
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for CGON
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$38.64 – $39.42
TARGET (TP)$70.75
STOP LOSS$35.91
RISK/REWARD1:10.2
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.31
52W High$46.01
52W Low$14.80
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $1.14M | $204,000 | $191,000 | $10.36M |
| Gross Profit | $1.14M | $204,000 | $176,000 | $10.35M |
| Gross Margin | 100.0% | 100.0% | 92.1% | 99.9% |
| Operating Income | $-114,666,000 | $-55,449,000 | $-35,246,000 | $-12,606,000 |
| Net Income | $-88,039,000 | $-48,607,000 | $-35,443,000 | $-12,839,000 |
| Net Margin | -7729.5% | -23827.0% | -18556.5% | -124.0% |
| EPS | $-1.41 | $-1.02 | $-0.66 | $-0.28 |
Company Overview
CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
10
91%
Hold / Neutral
1
9%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
10 Bullish1 Neutral/Bearish
Price Targets
$59
Average Target
↑ 50.4% Upside
Now
$23
Low
$59
Average
$90
High
Based on 14 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 11th 2025 | Wedbush | Initiation | Outperform | $70 |
| November 24th 2025 | Truist | Initiation | Buy | - |
| October 8th 2025 | Guggenheim | Initiation | Buy | $90 |
| August 19th 2025 | Piper Sandler | Initiation | Overweight | $55 |
| July 10th 2025 | Goldman | Resumed | Buy | $40 |
| May 2nd 2025 | JP Morgan | Initiation | Overweight | $41 |
| April 16th 2025 | Scotiabank | Initiation | Sector Perform | $23 |
| January 7th 2025 | TD Cowen | Initiation | Buy | - |
| October 24th 2024 | UBS | Initiation | Buy | $60 |
| September 23rd 2024 | RBC Capital Mkts | Initiation | Outperform | $66 |
| August 28th 2024 | ROTH MKM | Initiation | Buy | $65 |
| June 28th 2024 | BofA Securities | Initiation | Buy | $65 |
| February 20th 2024 | Cantor Fitzgerald | Initiation | Overweight | $75 |
| February 20th 2024 | Goldman | Initiation | Neutral | $42 |
| February 20th 2024 | Morgan Stanley | Initiation | Overweight | $55 |
Earnings History & Surprises
CGONBeat Rate
17%
Last 6 quarters
Avg Surprise
-2.4%
EPS vs Estimate
Beats / Misses
1/5
Last 12 quarters
Latest EPS
$-0.57
Q4 2025
EPS Surprise History
Q2 24
-2.9%
$-0.36vs$-0.35
Q3 24
+33.3%
$-0.28vs$-0.42
Q1 25
-17.1%
$-0.48vs$-0.41
Q2 25
-15.4%
$-0.45vs$-0.39
Q3 25
-10.2%
$-0.54vs$-0.49
Q4 25
-2.0%
$-0.57vs$-0.56
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 27, 2026 | $-0.63 | — | — | — |
Q4 2025 | Nov 14, 2025 | $-0.56 | $-0.57 | -2.0% | ✗ MISS |
Q3 2025 | Aug 8, 2025 | $-0.49 | $-0.54 | -10.2% | ✗ MISS |
Q2 2025 | May 13, 2025 | $-0.39 | $-0.45 | -15.4% | ✗ MISS |
Q1 2025 | Mar 28, 2025 | $-0.41 | $-0.48 | -17.1% | ✗ MISS |
Q4 2024 | Nov 14, 2024 | $-0.42 | — | — | — |
Q3 2024 | Aug 8, 2024 | $-0.42 | $-0.28 | +33.3% | ✓ BEAT |
Q2 2024 | May 9, 2024 | $-0.35 | $-0.36 | -2.9% | ✗ MISS |
Q1 2024 | Mar 26, 2024 | $-0.67 | — | — | — |
Latest News
Wedbush Initiates Coverage On CG Oncology with Outperform Rating, Announces Price Target of $70
📈 PositiveBenzinga•Dec 11, 2025, 02:20 PM
CG Oncology To Present Topline Data From BOND-003 Cohort P And First Results From CORE-008 Cohort A As Late-Breaking Abstracts At SUO 26th Annual Meeting
📈 PositiveBenzinga•Dec 5, 2025, 01:39 PM
Truist Securities Initiates Coverage On CG Oncology with Buy Rating, Announces Price Target of $62
📈 PositiveBenzinga•Nov 24, 2025, 05:55 PM
RBC Capital Maintains Outperform on CG Oncology, Raises Price Target to $61
📈 PositiveBenzinga•Nov 17, 2025, 01:19 PM
On November 10, 2025, CG Oncology's Robert Lapetina Resigned As Interim Financial Officer; Jim Detore Appointed As Principal Financial & Accounting Officer Effective Beginning November 17, 2025
➖ NeutralBenzinga•Nov 14, 2025, 10:35 PM•Also:
CG Oncology Q3 EPS $(0.57) Misses $(0.56) Estimate, Sales $1.666M Beat $65.300K Estimate
📈 PositiveBenzinga•Nov 14, 2025, 09:54 PM
CG Oncology jumps as Guggenheim starts at Buy on potential against bladder cancer
📈 PositiveSeeking Alpha•Oct 8, 2025, 03:31 PM
CG Oncology shares are trading higher after Guggenheim initiated coverage on the stock with a Buy rating and announced a $90 price target.
📈 PositiveBenzinga•Oct 8, 2025, 03:18 PM
JP Morgan Maintains Overweight on CG Oncology, Raises Price Target to $47
📈 PositiveBenzinga•Sep 26, 2025, 11:46 AM•Also:
Morgan Stanley Maintains Overweight on CG Oncology, Raises Price Target to $79
📈 PositiveBenzinga•Sep 17, 2025, 06:00 PM
HC Wainwright & Co. Reiterates Buy on CG Oncology, Maintains $75 Price Target
📈 PositiveBenzinga•Sep 15, 2025, 11:48 AM
Jones Trading Initiates Coverage On CG Oncology with Buy Rating, Announces Price Target of $50
📈 PositiveBenzinga•Sep 8, 2025, 04:26 PM
Cantor Fitzgerald Reiterates Overweight on CG Oncology, Maintains $75 Price Target
📈 PositiveBenzinga•Sep 8, 2025, 01:31 PM
HC Wainwright & Co. Reiterates Buy on CG Oncology, Maintains $75 Price Target
📈 PositiveBenzinga•Sep 8, 2025, 11:55 AM
HC Wainwright & Co. Reiterates Buy on CG Oncology, Maintains $75 Price Target
📈 PositiveBenzinga•Sep 5, 2025, 06:30 PM
CG Oncology shares are trading higher after the company announced updated data on BOND-003 Cohort C showing 12 additional patients with high risk non-muscle invasive bladder cancer were in complete response at 24 months.
📈 PositiveBenzinga•Sep 5, 2025, 02:49 PM
CG Oncology Announced Updated Data On BOND-003 Cohort C Showing 12 Additional Patients With High Risk Non-muscle Invasive Bladder Cancer Were In Complete Response At 24 Months, With Complete Response Rate Of 41.8%
📈 PositiveBenzinga•Sep 5, 2025, 11:04 AM
CG Oncology Completes Enrollment In Pivotal Phase 3 Trial For Bladder-Sparing Therapy In Intermediate-Risk Non-Muscle Invasive Bladder Cancer
📈 PositiveBenzinga•Sep 3, 2025, 12:14 PM
Frequently Asked Questions about CGON
What is CGON's current stock price?
CG Oncology, Inc. Common stock (CGON) is currently trading at $39.03 per share. The stock has moved +2.71% today.
What is the analyst price target for CGON?
The average analyst price target for CGON is $70.75, based on 1 analyst.
What sector is CG Oncology, Inc. Common stock in?
CG Oncology, Inc. Common stock operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is CGON's market cap?
CG Oncology, Inc. Common stock has a market capitalization of $2.93 billion, making it a mid-cap company.
Does CGON pay dividends?
No, CG Oncology, Inc. Common stock does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAAPG
ASCENTAGE PHARMA GROUP INTERNATIONAL
$29.31
Mkt Cap: $2.7B
APGE
Apogee Therapeutics, Inc.
$78.54
Mkt Cap: $4.3B
CELC
Celcuity Inc.
$101.16
Mkt Cap: $4.7B
CNTA
Centessa Pharmaceuticals plc
$24.85
Mkt Cap: $3.3B
IRON
Disc Medicine, Inc.
$80.04
Mkt Cap: $3.0B
LEGN
Legend Biotech Corporation
$21.92
Mkt Cap: $2.0B
RARE
Ultragenyx Pharmaceutical Inc.
$33.50
Mkt Cap: $3.2B
TARS
Tarsus Pharmaceuticals, Inc.
$81.40
Mkt Cap: $3.5B
TVTX
Travere Therapeutics, Inc.
$34.51
Mkt Cap: $3.1B
XENE
Xenon Pharmaceuticals Inc.
$44.10
Mkt Cap: $3.4B
Explore stocks similar to CGON for comparison